[Opinion] Bayer’s Eylea Set for Longer Treatment Intervals to Challenge Roche’s Vabysmo - Pharmaceutical Technology

Eylea 8 mg Approved in China for Wet AMD

The Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has approved Eylea 8 mg (aflibercept 8 mg) for the treatment of wet age-related macular degeneration (AMD) in China. The approval is based on positive results from the phase 3 PULSAR trial at week 48, which demonstrated comparable efficacy and safety of Eylea 8 mg with treatment intervals of 3 or 4 months (12 or 16 weeks) compared to standard of care …

Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo - Pharmaceutical Technology

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea 8mg.